Jafron Change To Netincome from 2010 to 2024

300529 Stock   30.48  0.41  1.36%   
Jafron Biomedical's Change To Netincome is decreasing over the years with slightly volatile fluctuation. Change To Netincome is expected to dwindle to about -13.3 M. From 2010 to 2024 Jafron Biomedical Change To Netincome quarterly data regression line had arithmetic mean of (10,976,581) and r-squared of  0.30. View All Fundamentals
 
Change To Netincome  
First Reported
2018-06-30
Previous Quarter
42.7 M
Current Value
-29.6 M
Quarterly Volatility
127.9 M
 
Covid
Check Jafron Biomedical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jafron Biomedical's main balance sheet or income statement drivers, such as Interest Expense of 57 M, Selling General Administrative of 363.6 M or Total Revenue of 1.2 B, as well as many indicators such as . Jafron financial statements analysis is a perfect complement when working with Jafron Biomedical Valuation or Volatility modules.
  
This module can also supplement various Jafron Biomedical Technical models . Check out the analysis of Jafron Biomedical Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Jafron Stock

Jafron Biomedical financial ratios help investors to determine whether Jafron Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Jafron with respect to the benefits of owning Jafron Biomedical security.